Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients
Bin Ni, Cameron R. Wolfe, Sana Arif, Manuela Carugati, Madeleine R. Heldman, Julia A. Messina, Rachel A. Miller, Jennifer L. Saullo, Arthur W. Baker, Eileen K Maziarz
Abstract
We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.
Topics & Concepts
MedicineCytomegalovirus infectionCytomegalovirusIntensive care medicineOrgan transplantationSolid organCytomegalovirus infectionsTransplantationInternal medicineImmunologyHuman cytomegalovirusHuman immunodeficiency virus (HIV)HerpesviridaeViral diseaseVirusCytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsMosquito-borne diseases and control